{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:23:24Z","timestamp":1789752204670,"version":"4.0.1"},"reference-count":107,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/crd.0b013e3182503e2d","type":"journal-article","created":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T12:25:26Z","timestamp":1330172726000},"page":"209-221","source":"Crossref","is-referenced-by-count":25,"title":["Newer Anticoagulants in Cardiovascular Disease"],"prefix":"10.1097","volume":"20","author":[{"given":"Abhishek","family":"Maan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Y.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy N.","family":"Ruskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Kevin","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.","volume":"20","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/CIRCOUTCOMES.110.957738","article-title":"Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA).","volume":"4","author":"Rose","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","article-title":"Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation.","volume":"37","author":"Birman-Deych","year":"2006","journal-title":"Stroke"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200847090-00002","article-title":"Pharmacogenetics of oral anticoagulants: a basis for dose individualization.","volume":"47","author":"Stehle","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2008-09-176222","article-title":"Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.","volume":"113","author":"Perez-Andreu","year":"2009","journal-title":"Blood"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data.","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1161\/STROKEAHA.107.488007","article-title":"SPORTIF III and V Investigators. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.","volume":"38","author":"Ford","year":"2007","journal-title":"Stroke"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.thromres.2008.02.017","article-title":"EXTEND Study Group. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.","volume":"123","author":"Agnelli","year":"2009","journal-title":"Thromb Res"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran.","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb Haemost"},{"key":"R17-1-20210203","first-page":"e136","article-title":"Dabigatran inhibits both clot-bound and fluid-phase thrombin in vitro: comparison to heparin and hirudin.","volume":"28","author":"van Ryn","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.","volume":"48","author":"Stangier","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIR.0b013e31820f14c0","article-title":"American College of Cardiology FoundationAmerican Heart Association Task Force. 2011 ACCFAHAHRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on practice guidelines.","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial.","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1160\/TH08-07-0493","article-title":"Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.","volume":"101","author":"Wolowacz","year":"2009","journal-title":"Thromb Haemost"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","article-title":"Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.","volume":"141","author":"McKellar","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.thromres.2010.06.011","article-title":"In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.","volume":"126","author":"Maegdefessel","year":"2010","journal-title":"Thromb Res"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor.","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2005.03.009","article-title":"Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.","volume":"514","author":"Furugohri","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects.","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/00498250500250493","article-title":"Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs.","volume":"35","author":"Weinz","year":"2005","journal-title":"Xenobiotica"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin.","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R41-1-20210203","first-page":"702","article-title":"No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin.","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2006.02776.x","article-title":"Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen.","volume":"63","author":"Kubitza","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2009.03503.x","article-title":"Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.","volume":"7","author":"Wong","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"R48-1-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism.","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"ATLAS ACS-TIMI 46 Study Group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"R54-1-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome.","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe1112770","article-title":"A new era in secondary prevention after acute coronary syndrome.","volume":"366","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"R56-1-20210203","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11239-011-0621-6","article-title":"Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.","volume":"32","author":"Kaeberich","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"R58-1-20210203","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R59-1-20210203","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans.","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R60-1-20210203","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/j.1538-7836.2008.03092.x","article-title":"Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits.","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R61-1-20210203","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/13543784.15.8.843","article-title":"Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.","volume":"15","author":"Kubitza","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R62-1-20210203","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1021\/jm070245n","article-title":"Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo3,4-cpyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.","volume":"50","author":"Pinto","year":"2007","journal-title":"J Med Chem"},{"key":"R63-1-20210203","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R64-1-20210203","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation.","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"R65-1-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"R66-1-20210203","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R68-1-20210203","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"R69-1-20210203","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"R70-1-20210203","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome.","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"R71-1-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH07-04-0312","article-title":"Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.","volume":"98","author":"Zafar","year":"2007","journal-title":"Thromb Haemost"},{"key":"R72-1-20210203","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.","volume":"6","author":"Furugohri","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R73-1-20210203","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R74-1-20210203","first-page":"1124","article-title":"Effect of renal function on edoxaban pharmacokinetics (PK) and on population PKPK-PD model (abstract).","volume":"49","author":"Ridout","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"R76-1-20210203","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"R77-1-20210203","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"R78-1-20210203","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH10-02-0142","article-title":"Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.","volume":"104","author":"Raskob","year":"2010","journal-title":"Thromb Haemost"},{"key":"R80-1-20210203","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"R82-1-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"R83-1-20210203","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehp318","article-title":"Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.","volume":"30","author":"Lip","year":"2009","journal-title":"Eur Heart J"},{"key":"R84-1-20210203","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1160\/TH09-07-0509","article-title":"Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation.","volume":"103","author":"Olsson","year":"2010","journal-title":"Thromb Haemost"},{"key":"R85-1-20210203","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1160\/TH08-09-0586","article-title":"Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.","volume":"101","author":"Deinum","year":"2009","journal-title":"Thromb Haemost"},{"key":"R86-1-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R87-1-20210203","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1160\/TH05-05-0347","article-title":"Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.","volume":"94","author":"Paccaly","year":"2005","journal-title":"Thromb Haemost"},{"key":"R88-1-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0091270005281817","article-title":"Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 23 simulation of exposure.","volume":"46","author":"Paccaly","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R89-1-20210203","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.106.653428","article-title":"SEPIA-PCI Trial Investigators. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.","volume":"115","author":"Cohen","year":"2007","journal-title":"Circulation"},{"key":"R90-1-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(09)61454-9","article-title":"Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.","volume":"374","author":"Sabatine","year":"2009","journal-title":"Lancet"},{"key":"R91-1-20210203","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"R92-1-20210203","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/j.thromres.2010.08.025","article-title":"Antithrombotic activity of the novel oral anticoagulant, Tecarfarin Sodium 3-4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl-2-oxo-2H-chromen-4-olate in animal models.","volume":"126","author":"Bowersox","year":"2010","journal-title":"Thromb Res"},{"key":"R93-1-20210203","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1476-5381.2009.00420.x","article-title":"Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.","volume":"158","author":"Choppin","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R94-1-20210203","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/0091270010370588","article-title":"Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.","volume":"51","author":"Bavisotto","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R95-1-20210203","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.109.856120","article-title":"The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.","volume":"120","author":"Ellis","year":"2009","journal-title":"Circulation"},{"key":"R96-1-20210203","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.","volume":"5","author":"Agnelli","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R97-1-20210203","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/FJC.0b013e3181e2bfcf","article-title":"Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.","volume":"56","author":"Kawamura","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"R98-1-20210203","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1160\/TH10-05-0273","article-title":"A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"R99-1-20210203","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1538-7836.2009.03298.x","article-title":"The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.","volume":"7","author":"Veyrat-Follet","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R102-1-20210203","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1538-7836.2008.03089.x","article-title":"Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.","volume":"6","author":"Savi","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R104-1-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(11)61505-5","article-title":"CASSIOPEA Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.","volume":"379","author":"Buller","year":"2012","journal-title":"Lancet"},{"key":"R105-1-20210203","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(11)61580-8","article-title":"Idrabiotaparinux treatment for venous thromboembolism.","volume":"379","author":"Eikelboom","year":"2012","journal-title":"Lancet"},{"key":"R106-1-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/0929867013373822","article-title":"Perspectives on factor Xa inhibition.","volume":"8","author":"Rai","year":"2001","journal-title":"Curr Med Chem"},{"key":"R107-1-20210203","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2006.02667.x","article-title":"Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.","volume":"62","author":"Liesenfeld","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R108-1-20210203","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000081505","article-title":"The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.","volume":"33","author":"Nowak","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"R109-1-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1600-0609.2009.01230.x","article-title":"Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.","volume":"82","author":"Haas","year":"2009","journal-title":"Eur J Haematol"},{"key":"R115-1-20210203","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"R116-1-20210203","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1161\/CIRCULATIONAHA.111.054510","article-title":"Reversal of new oral anticoagulants.","volume":"124","author":"Battinelli","year":"2011","journal-title":"Circulation"},{"key":"R117-1-20210203","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.","volume":"8","author":"Paty","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R118-1-20210203","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery.","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R119-1-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","article-title":"The new oral anticoagulants.","volume":"115","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"R121-1-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"R122-1-20210203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann Intern Med"},{"key":"R123-1-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.amjopharm.2009.07.002","article-title":"Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.","volume":"7","author":"Leey","year":"2009","journal-title":"Am J Geriatr Pharmacother"},{"key":"R124-1-20210203","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.jacc.2010.03.009","article-title":"Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).","volume":"55","author":"Epstein","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R126-1-20210203","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(11)61294-4","article-title":"Self-Monitoring Trialist Collaboration. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data.","volume":"379","author":"Heneghan","year":"2012","journal-title":"Lancet"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0b013e3182503e2d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:43:03Z","timestamp":1786048983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201209000-00001"}},"subtitle":["A Systematic Review of the Literature"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e3182503e2d","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}